[go: up one dir, main page]

MXPA06010667A - Metodos combinatorios y composiciones para el tratamiento de melanoma. - Google Patents

Metodos combinatorios y composiciones para el tratamiento de melanoma.

Info

Publication number
MXPA06010667A
MXPA06010667A MXPA06010667A MXPA06010667A MXPA06010667A MX PA06010667 A MXPA06010667 A MX PA06010667A MX PA06010667 A MXPA06010667 A MX PA06010667A MX PA06010667 A MXPA06010667 A MX PA06010667A MX PA06010667 A MXPA06010667 A MX PA06010667A
Authority
MX
Mexico
Prior art keywords
melanoma
melanoma tumor
agent
treating
mammal
Prior art date
Application number
MXPA06010667A
Other languages
English (en)
Inventor
Gavin P Robertson
Mark Kester
Lakshman Sandirasegarane
Arati Sharma
Original Assignee
Penn State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Penn State Res Found filed Critical Penn State Res Found
Publication of MXPA06010667A publication Critical patent/MXPA06010667A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invencion proporciona una base racional para combatir terapias dirigidas junto con quimioterapeuticos seleccionados, que actualmente no existen para el tratamiento de melanoma. A presente invencion se basa e el descubrimiento de los presentes inventores de Akt3 regula la apoptosis y V599E B-Raf regula el crecimiento y el desarrollo vascular en el melanoma. Los inventores son los primeros en reconocer un regimen terapeutico dirigido combinado, efectivo, para el tratamiento del melanoma. En una modalidad, la invencion proporciona un metodo para inducir apoptosis en una celula de tumor de melanoma al reducir la actividad de Akt3. En todavia otra modalidad, la invencion proporciona un metodo para inducir la apoptosis en una celula de tumor de melanima que comprende poner en contacto una celula de tumor de melanoma con un agente que reduce la actividad de Akt3. Consecuentemente, el metodo proporcionado restaura a sensibilidad apototica normal a una celula de tumor de la melanoma,. Para de esta manera permitir la adjministracion de una concentracion inferior de agentes quimioterapeuticos que dan por resultado toscicidad dsiminuida a un paciente. Los presentes inventores contemplan un metodo para tratar un tumor de melanoma en un mamifero que comprende: la administracion a un tumor de melanoma e una cantidad efectiva de un agente para inducir apoptosis; y la administracion a u n tumor de melanoma de una cantidad efectiva de un gene para reducir la angiogenesis y la proliferacion celular. Tambien se divulga en la presente un metodo para tratar un melanoma en un mamifero que comprende: la administracion a un tumor de melanoma e un mamifero de una cantidad efectiva de un agente que reduce la actividad de Akt3; la administracion a un tumor de melanoma en un mamifero de una cantidad efectiva de un agente que reduce la actividad de V599E B-Raf, para de esta manera tratar un tumor e melanoma. En otro aspecto, la invencion proporciona una composicion farmaceutica para tratar un tumor de melanoma que comprende: un agente que reduce la actividad de Akt3; y un portador.
MXPA06010667A 2004-03-19 2005-03-18 Metodos combinatorios y composiciones para el tratamiento de melanoma. MXPA06010667A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55450904P 2004-03-19 2004-03-19
PCT/US2005/008950 WO2005089443A2 (en) 2004-03-19 2005-03-18 Combinatorial methods and compositions for treatment of melanoma

Publications (1)

Publication Number Publication Date
MXPA06010667A true MXPA06010667A (es) 2007-07-04

Family

ID=34994352

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06010667A MXPA06010667A (es) 2004-03-19 2005-03-18 Metodos combinatorios y composiciones para el tratamiento de melanoma.

Country Status (9)

Country Link
US (4) US20050267060A1 (es)
EP (1) EP1744788A4 (es)
JP (1) JP2007530453A (es)
CN (1) CN101389345A (es)
AU (1) AU2005223649A1 (es)
BR (1) BRPI0508970A (es)
CA (1) CA2560269A1 (es)
MX (1) MXPA06010667A (es)
WO (1) WO2005089443A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
JP2002534468A (ja) 1999-01-13 2002-10-15 バイエル コーポレイション ｐ３８キナーゼ阻害剤としてのω−カルボキシアリール置換ジフェニル尿素
PT1478358E (pt) 2002-02-11 2013-09-11 Bayer Healthcare Llc Tosilato de sorafenib para o tratamento de doenças caracterizadas por angiogénese anormal
DK1636585T3 (da) 2003-05-20 2008-05-26 Bayer Pharmaceuticals Corp Diarylurinstoffer med kinasehæmmende aktivitet
PT1663978E (pt) 2003-07-23 2008-02-15 Bayer Pharmaceuticals Corp Omega-carboxiaril difenil ureia substituída por flúor para o tratamento e a prevenção de doenças e estados patológicos
ES2400689T3 (es) 2004-10-18 2013-04-11 Amgen, Inc Compuestos de tiadiazol y métodos de uso
MX2007014920A (es) * 2005-05-27 2008-04-09 Bayer Healthcare Ag Politerapia que comprende diarilureas para el tratamiento de enfermedades.
US20070178494A1 (en) * 2005-11-14 2007-08-02 James Elting Methods for prediction and prognosis of cancer, and monitoring cancer therapy
US20080306148A1 (en) 2007-04-13 2008-12-11 The Penn State Research Foundation Anti-cancer compositions and methods
WO2009011871A2 (en) 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of pkb
CA2692713A1 (en) 2007-07-17 2009-01-22 Amgen Inc. Heterocyclic modulators of pkb
KR101573026B1 (ko) 2007-07-25 2015-11-30 에자이 알앤드디 매니지먼트 가부시키가이샤 암 치료에서 이용하기 위한 멀티키나아제 억제제
WO2009058908A2 (en) * 2007-10-29 2009-05-07 Eisai R & D Management Co., Ltd. Methods for prognosing the ability of a zearalenone analog compound to treat cancer
US20100029657A1 (en) * 2008-02-29 2010-02-04 Wyeth Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
WO2010091354A2 (en) 2009-02-06 2010-08-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Akt tyrosine 176 phosphorylation cancer biomarker
JP5641232B2 (ja) * 2010-11-24 2014-12-17 石川県公立大学法人 オゴノリ由来のシクロオキシゲナーゼの遺伝子及び該遺伝子を利用するプロスタグランジン類生産方法
WO2012154942A2 (en) 2011-05-10 2012-11-15 The Penn State Research Foundation Ceramide anionic liposome compositions
WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
WO2015041533A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
EP3526259A4 (en) * 2016-10-13 2020-06-17 Dana-Farber Cancer Institute, Inc. COMPOSITIONS AND METHODS FOR PREDICTING THE REACTION AND RESISTANCE TO A CTLA4 BLOCKAGE IN MELANOMAS USING A GENE EXPRESSION SIGNATURE
MA50532A (fr) 2017-11-03 2020-09-09 Univ Virginia Patent Foundation Compositions et méthodes pour le traitement de cancers
CN110476953B (zh) * 2019-09-09 2021-11-12 广州中鑫基因医学科技有限公司 一种细胞活性保存液以及疾病检测试剂盒
JP2023525757A (ja) * 2020-05-08 2023-06-19 ジョージアミューン・インコーポレイテッド Ａｋｔ３モジュレーター
CN111759794B (zh) * 2020-07-14 2023-07-21 中山大学 一种治疗黑色素瘤的微针及其制备方法
CN117110467B (zh) * 2023-08-16 2024-08-20 苏州方昆医药科技有限公司 一种醇或酚类化合物的柱前化学衍生化方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843974A (en) * 1995-06-06 1998-12-01 Eli Lilly And Company Methods of inhibiting melanoma using Benzothiophenes as cytotoxic agents per se
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US20030035790A1 (en) * 1999-01-15 2003-02-20 Shu-Hsia Chen Combination therapy for the prevention or treatment of cancer, inflammatory disorders or infectious diseases in a subject
CN1390219A (zh) * 1999-09-17 2003-01-08 艾博特股份有限两合公司 作为治疗剂的吡唑并嘧啶类
US6187586B1 (en) * 1999-12-29 2001-02-13 Isis Pharmaceuticals, Inc. Antisense modulation of AKT-3 expression
US20030004174A9 (en) * 2000-02-17 2003-01-02 Armistead David M. Kinase inhibitors
US6809194B1 (en) * 2000-05-10 2004-10-26 Chiron Corporation Akt3 inhibitors
WO2002083064A2 (en) * 2001-04-10 2002-10-24 Merck & Co., Inc. A method of treating cancer
CA2444821C (en) * 2001-04-24 2012-07-10 Merck Patent Gesellschaft Mit Beschraenkter Haftung Combination therapy using anti-angiogenic agents and tnfa
WO2003047523A2 (en) * 2001-12-04 2003-06-12 Onyx Pharmaceuticals, Inc. Raf-mek-erk pathway inhibitors to treat cancer
US6998391B2 (en) * 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
AU2003237121A1 (en) * 2002-04-26 2003-11-10 Vertex Pharmaceuticals Incorporated Pyrrole derivatives as inhibitors of erk2 and uses thereof
WO2003093430A2 (en) * 2002-05-03 2003-11-13 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for use in preparing sirnas
EP2263679B1 (en) * 2002-08-21 2014-10-08 The University Of British Columbia RNAi targeting cancer-related proteins
CA2494764C (en) * 2002-08-21 2013-04-23 The University Of British Columbia Treatment of melanoma by reduction in clusterin levels
EP2305813A3 (en) * 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna
US20080161547A1 (en) * 2002-11-14 2008-07-03 Dharmacon, Inc. siRNA targeting serine/threonine protein kinase AKT
US20050221354A1 (en) * 2004-02-18 2005-10-06 Wyeth Nucleic acid arrays for monitoring expression profiles of drug target genes

Also Published As

Publication number Publication date
US20140348901A1 (en) 2014-11-27
US20130209546A1 (en) 2013-08-15
AU2005223649A1 (en) 2005-09-29
CN101389345A (zh) 2009-03-18
WO2005089443A3 (en) 2009-04-23
CA2560269A1 (en) 2005-09-29
WO2005089443A2 (en) 2005-09-29
EP1744788A2 (en) 2007-01-24
US20130217949A1 (en) 2013-08-22
US20050267060A1 (en) 2005-12-01
BRPI0508970A (pt) 2007-08-21
JP2007530453A (ja) 2007-11-01
EP1744788A4 (en) 2010-08-18

Similar Documents

Publication Publication Date Title
MXPA06010667A (es) Metodos combinatorios y composiciones para el tratamiento de melanoma.
NZ593343A (en) Combination cancer treatment conprising Abraxane and an inflamatory inhibitor
NZ605865A (en) Cns delivery of therapeutic agents
CN101001623A (zh) 抗癌效果增强剂
NZ602635A (en) Methods of enhancing drug delivery and effectiveness of therapeutic agents
Cha et al. Feasibility of sorafenib combined with local radiotherapy in advanced hepatocellular carcinoma
EA200800663A1 (ru) Способ и средство профилактики и лечения нарушенного дыхания во время сна
Lhomme et al. Phase II trial of vinorelbine in patients with advanced and/or recurrent cervical carcinoma: an EORTC Gynaecological Cancer Cooperative Group Study
EA200700214A1 (ru) Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией
MX2009004051A (es) Uso de antagonistas de il-1 para tratar gota y pseudo gota.
Merenzon et al. Nitric oxide synthase inhibitors as potential therapeutic agents for gliomas: A systematic review
MX2007005581A (es) Regimen de dosificacion mejorada de temozolomida para el tratamiento de cancer con base en el nivel de o6-metilguanidi-adn metiltransferasa del paciente.
DE602005009176D1 (de) Behandlung von t-zellen-lymphom mittels 10-propargyl-10-deazaaminopterin
Griffin et al. Preferential action of arsenic trioxide in solid-tumor microenvironment enhances radiation therapy
GB0405349D0 (en) Cancer therapy and medicaments therefor
TW200501948A (en) Composition for improving cognition and memory
WO2005009217A3 (en) Diagnosis of pre-cancerous conditions using pcdgf agents
MXPA02009984A (es) Metodo y composicion para el tratamiento del cancer mediante la administracion de agentes quimioterapeuticos que inducen la apoptosis.
Lai et al. Combined effect of topical arsenic trioxide and radiation therapy on skin-infiltrating lesions of breast cancer—a pilot study
Zustovich et al. Gemcitabine for the treatment of classic Kaposi's sarcoma: a case series
EA201270551A1 (ru) Лечение нейротоксичности, ассоциированной с комбинациями 5-fu или его пролекарств с ингибиторами dpd
EA200801670A1 (ru) Комбинированная противораковая терапия с перфузией изолированного органа
Bleiberg Colorectal cancer: The challenge
Nunez-Rodriguez et al. Volatile general anesthetics and oncologic surgery: A safe choice
Huang et al. Lumbar sympathetic ganglion block for cancer-associated secondary lower limb lymphedema: a retrospective study

Legal Events

Date Code Title Description
FG Grant or registration